Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia participants to accelerate biomarker discovery. Data will be openly shared and linked with clinical and genetic information to support AI-driven research and improve diagnosis and treatment development. This initiative is part of the CLARiTI alliance and aims to deepen understanding of neurodegenerative diseases through large-scale, multi-marker blood testing.
Solana's Agave 4.2 upgrade, activated on mainnet starting August 17, 2026, introduces three key improvements: a 90% reduction in on-chain storage rent, a 3.3-fold increase in maximum transaction size, and a staged reduction of slot time from 400ms to...
XRP traded just below $1, slipping 0.4% on Aug 18, despite a 280% surge in large whale transactions and rising derivatives activity on Binance. The price remains under pressure, failing to sustain a rebound above the key $1 level, which now acts as r...
StoneCo reported disappointing Q2 results with revenue growing only 2.5% year-over-year and earnings per share falling short of expectations. The company is increasingly relying on credit services to drive growth, but rising delinquencies raise conce...
Most leading US publicly traded managed care insurers increased their full-year earnings estimates after reporting second quarter 2026 results. This comes despite facing higher medical costs and shifts in membership, especially within Medicare Advant...
Zoetis is experiencing its worst stock decline ever, down 70% from its peak, due to weaker U.S. veterinary clinic visits and increased competition in key animal health segments. Despite aggressive competitor promotions, Zoetis maintains strong profit...
